Valion Bio (VBIO) Return on Sales (2021 - 2026)

Valion Bio's Return on Sales history runs 5 years deep, the most recent figure standing at 0.01% for Q4 2025.

• In Q4 2025, Return on Sales rose 9.0% year-over-year to 0.01%; the TTM figure through Dec 2025 stood at 0.15% (down 8.0% YoY), while the FY2025 annual figure was 0.02%, down 1.0% from the prior year.
• Return on Sales for Q4 2025 stood at 0.01%, up from 0.17% in the prior quarter.
• The five-year high for Return on Sales was 0.01% in Q4 2025, with the low at 0.22% in Q2 2025.
• The 5-year median for Return on Sales is 0.06% (2021), against an average of 0.08%.
• Peak annual rise in Return on Sales reached 9 bps in 2025, while the deepest fall reached 17 bps in 2025.
• Valion Bio's Return on Sales stood at 0.06% in 2021, then gained by 4 bps to 0.06% in 2022, then slipped by 14 bps to 0.06% in 2023, then plunged by 30 bps to 0.08% in 2024, then jumped by 111 bps to 0.01% in 2025.
• Business Quant data shows VBIO's Return on Sales at 0.01% in Q4 2025, 0.17% in Q3 2025, and 0.22% in Q2 2025.